HRS news

Latest 1 stories · newest Nov 6, 2026

HRS

Hengrui and Braveheart Bio present 52-week data for HRS/BHB-1893 in HCM study

Braveheart and Hengrui presented clinical data at AHA Scientific Sessions 2026 showing that HRS/BHB-1893 significantly improved exercise capacity and reduced LVOT gradients, a development that supports the initiation of the company's planned clinical development in China.

Regulatory Nov 6, 2026 sentiment +0.70 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same HRS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/HRS/newsSTART FREE